Phase 2 Study of Pembrolizumab and BEAM Therapy with Stem Cell Transplant for Relapsed Hodgkin Lymphoma

Inclusion Criteria

• Eligible for a stem cell transplant using the BEAM therapy regimen.
• Have a performance status score indicating good health (KPS greater than 70 or ECOG 0 or 1).
• Have adequate organ function and blood counts within 14 days before joining the study.
• If positive for hepatitis B, must have been on antiviral therapy for at least 4 weeks and have no detectable virus before starting the study.
• If previously infected with hepatitis C, must have no detectable virus at screening.
• If HIV-positive, must have well-controlled HIV on antiretroviral therapy.

Exclusion Criteria

• History of severe autoimmune reaction to PD-1 inhibitors.
• Received radiation therapy within 2 weeks before starting the study or have radiation-related side effects needing steroids.
• Received a live vaccine within 30 days before starting the study (killed vaccines are allowed).
• Received chemotherapy within 3 weeks before starting the study.
• Have active disease in the central nervous system.
• Have a history of or active autoimmune disease needing systemic steroids or autoimmune drugs, except for certain conditions like vitiligo or controlled hypothyroidism.
• Have had a tissue or organ transplant from another person.
• Pregnant or breastfeeding women cannot participate due to potential risks. Women of childbearing potential must have a negative pregnancy test within 14 days before joining the study.